Citrobacter Amalonaticus: Infections, Symptoms, & Treatment

Citrobacter amalonaticus is a gram-negative bacterium that most commonly causes urinary tract infections, particularly in hospitalized patients, though it can also invade the bloodstream, surgical wounds, and the abdominal cavity. It belongs to a genus that has drawn increasing attention from infectious disease specialists because of its ability to acquire resistance to powerful antibiotics, including carbapenems, which are often drugs of last resort. While it is far less commonly encountered than pathogens like E. coli, the infections it does cause tend to cluster in healthcare settings and in patients who are already vulnerable.

What Citrobacter Amalonaticus Actually Is

Citrobacter is a genus of bacteria in the Enterobacteriaceae family, the same broad group that includes E. coli, Klebsiella, and Salmonella. Within the genus, species are separated by a handful of metabolic traits: whether they produce certain enzymes, break down specific sugars, or generate hydrogen sulfide. C. amalonaticus is distinguished from its close relatives like C. koseri and the C. freundii complex based on characteristics such as indole production, malonate utilization, and acid production from certain sugar alcohols.¹ These differences sound minor, but they matter clinically because different Citrobacter species carry different resistance genes and behave differently in infections.

Despite looking nearly identical to C. koseri under many standard lab tests, C. amalonaticus carries a distinct set of beta-lactamase genes, the enzymes bacteria use to chew up penicillin-type antibiotics. Genetic analysis of the 16S rRNA gene, a molecular fingerprint used to classify bacteria, has confirmed that some isolates previously lumped in with C. koseri are in fact C. amalonaticus.² This matters for treatment: picking the wrong antibiotic because the lab misidentified the species can mean a drug that looks effective on paper but fails in the patient.

Where It Lives and How People Get Exposed

C. amalonaticus lives in the environment, in soil, water, and sewage, and it also inhabits the human gastrointestinal tract. Researchers have isolated it from fecal samples of healthy volunteers with no signs of infection, confirming it can be a normal, quiet resident of the gut.³ This is typical of opportunistic pathogens: the bacterium causes no trouble when it stays in its lane, but it becomes dangerous when it reaches a body site where it does not belong, or when the patient’s immune defenses are compromised.

The transition from harmless gut resident to disease-causing pathogen usually involves healthcare. Urinary catheters, intravenous lines, surgical incisions, and dialysis catheters all create entry points. A systematic review of Citrobacter infections in hospitals found that common outbreak sources included sinks, toilets, contaminated food, and even injection materials.⁴ In other words, the bacterium often travels through hospital plumbing and surfaces before reaching a patient.

The Infections It Causes

Urinary tract infections are the single most common presentation. A detailed study conducted over 13 years at a hospital in Marseille, France, found that 80 percent of C. amalonaticus infections were UTIs. Most were hospital-acquired, and about 60 percent of all infections occurred in male patients. An unexpected finding was that nearly a third of infected patients were young children under 11, a proportion significantly higher than what you would see with E. coli UTIs in the same population.⁵ The study also documented a sharp spike in cases beginning in 2012, with statistically more infections in the years that followed than in the decade before, suggesting either improved detection or a genuine increase in prevalence.

Bloodstream infections (bacteremia) are less common but more serious. A large population-based study of Citrobacter bloodstream infections found that the median age of affected patients was 77, and almost half of those infections originated from the urinary tract, meaning a UTI that spread to the blood. About 4 percent of episodes involved septic shock, 7 percent required intensive care, and the 90-day mortality rate was 18 percent.⁶ That study covered all Citrobacter species rather than C. amalonaticus alone, but the pattern is consistent: elderly, hospitalized or healthcare-associated patients bear the greatest burden.

Rarer presentations round out the clinical picture. A published case report described the first documented peritoneal dialysis-related peritonitis caused by C. amalonaticus, in a 64-year-old woman on continuous ambulatory peritoneal dialysis who developed cloudy dialysate and abdominal pain.⁷ Surgical site infections have also been documented, particularly when the infecting strain carries high-level drug resistance.⁸ And in one striking case, a 62-year-old man developed carbapenem-resistant C. amalonaticus bacteremia just one day after a urological procedure, presenting with gross blood in his urine, fever, and chills.⁹ That patient had no underlying immune problems, a reminder that healthy people are not entirely exempt when invasive procedures are involved.

Symptoms to Watch For

Because C. amalonaticus infections overwhelmingly affect the urinary tract, the most common symptoms are what you would expect from any bacterial UTI: burning or pain during urination, frequent or urgent need to urinate, cloudy or foul-smelling urine, and sometimes lower abdominal or flank pain. In catheterized patients, the first sign may simply be a change in urine appearance or a new fever, since the catheter itself masks some of the usual urinary symptoms.

When the infection spreads to the bloodstream, the symptoms escalate. Fever, chills, rapid heart rate, confusion (particularly in older adults), and a drop in blood pressure are hallmarks of bacteremia progressing toward sepsis. The Marseille study noted that hospital-acquired infections were the majority, so clinicians caring for patients with indwelling catheters, recent surgery, or dialysis access should have Citrobacter on their radar when a nosocomial fever workup is underway.

Peritonitis from dialysis-related infection typically presents with abdominal pain and cloudy dialysate fluid, as in the case described above. Surgical site infections show the standard signs: redness, swelling, warmth, drainage, and pain at the wound. None of these symptom profiles are unique to C. amalonaticus; only culture results distinguish it from other gram-negative bacteria causing the same syndromes.

Who Is Most at Risk

The recurring theme across the literature is healthcare exposure. The majority of C. amalonaticus infections are nosocomial or healthcare-associated, meaning they develop in patients who are already in a hospital, recently discharged, or receiving ongoing medical treatment like dialysis.⁵ Age is a major risk factor for bloodstream infections: the median age in the population-based bacteremia study was 77.⁶

The other at-risk group that stands out is young children. The Marseille data showed a disproportionate number of C. amalonaticus UTIs in children under 11 compared to E. coli.⁵ The reasons are not entirely clear, but the immature immune system and, in hospitalized children, the frequent use of urinary instrumentation likely contribute. Patients on dialysis, those with indwelling devices, and anyone recently receiving broad-spectrum antibiotics (which can clear competing bacteria and open space for resistant organisms) also face elevated risk.

How It Is Diagnosed

Identifying C. amalonaticus to the species level is not trivial. Traditional biochemical testing, the metabolic fingerprinting approach, works reasonably well for the Citrobacter genus but can stumble when distinguishing closely related species. A comparison study found that biochemical methods identified about 90 percent of Citrobacter strains to the species level, while MALDI-TOF mass spectrometry, a newer technique that identifies bacteria by the unique pattern of proteins they contain, managed about 95 percent. The small number of discrepancies between the two methods all involved species within the C. freundii complex, not C. amalonaticus specifically, but the study concluded that MALDI-TOF was faster and more accurate overall.¹⁰

In practice, most clinical labs in well-resourced hospitals now use MALDI-TOF as a first-line identification tool. The result comes back within minutes rather than the day or more needed for biochemical panels to incubate. Once the species is identified, susceptibility testing determines which antibiotics will actually work. That step is increasingly critical given the resistance profiles these organisms carry.

The Antibiotic Resistance Problem

This is where C. amalonaticus gets genuinely worrying. The Citrobacter genus as a whole has been acquiring resistance mechanisms at an alarming pace, including the ability to invade, colonize, form biofilms on surfaces and devices, and produce toxins.¹¹ But what has raised red flags most recently is carbapenem resistance. Carbapenems are broad-spectrum antibiotics reserved for infections that resist nearly everything else, so when bacteria develop ways to defeat them, the treatment toolbox shrinks dramatically.

A case study using whole-genome sequencing found a C. amalonaticus strain recovered from a surgical site infection that co-produced three different carbapenem-destroying enzymes at once. The strain showed very high resistance to both imipenem and meropenem, two of the most commonly used carbapenems. Genetic analysis revealed that one of the resistance genes was permanently integrated into the bacterium’s chromosome, while two others were carried on mobile genetic elements, the plasmids that bacteria can swap with each other like trading cards.⁸ The combination of chromosomal and plasmid-borne resistance means the bacterium both passes the trait reliably to its own offspring and can spread it horizontally to unrelated bacteria in the same environment.

The case of the man who developed bacteremia after a urological procedure illustrates the clinical fallout. His C. amalonaticus isolate was carbapenem-resistant, and he simultaneously developed a bloodstream infection with vancomycin-resistant Enterococcus, another difficult-to-treat organism.⁹ Managing two multi-drug-resistant bloodstream infections at once in any patient is a nightmare scenario for infectious disease teams.

Treatment Approaches

When C. amalonaticus is susceptible to standard antibiotics, treatment follows the same principles used for other gram-negative infections. UTIs may respond to fluoroquinolones, trimethoprim-sulfamethoxazole, or aminoglycosides, depending on susceptibility results. The peritonitis case mentioned earlier was successfully treated with intraperitoneal netilmicin (an aminoglycoside) and oral ciprofloxacin, and the dialysis catheter was saved.⁷ Bloodstream infections typically require intravenous antibiotics and sometimes source control, such as removing an infected catheter or draining an abscess.

The challenge comes with resistant strains. When carbapenems fail, clinicians turn to last-line agents like colistin, ceftazidime-avibactam, or newer beta-lactam/beta-lactamase inhibitor combinations, depending on the specific resistance genes present. These drugs are more toxic, harder to dose, or less well studied in Citrobacter specifically, making management considerably more complicated. Susceptibility testing becomes non-negotiable; empiric therapy based on guesswork has a real chance of missing.

One area of active research is phage therapy, the use of viruses that specifically infect and kill bacteria. A laboratory study tested a bacteriophage against C. amalonaticus both alone and in combination with eight different antibiotics. The results showed that combining even very low numbers of phages with sub-lethal concentrations of antibiotics produced synergistic killing, meaning the combination worked better than either component alone.¹² This is still pre-clinical work, not something available in routine practice, but it represents a potential future tool for infections where conventional antibiotics have been exhausted.

Hospital Infection Control

Preventing C. amalonaticus from spreading in healthcare settings is a challenge partly because the bacterium lives in the hospital’s own plumbing. The systematic review of Citrobacter outbreaks found that after 2016, reported outbreaks increased in frequency. In those outbreaks, for every patient who developed an active infection, roughly three others were colonized (carrying the bacterium without symptoms), making silent spread easy. The case-fatality ratio across these outbreaks was about 7 percent. Standard control measures included environmental cleaning, isolating colonized or infected patients, and reinforcing hand hygiene, yet only about half of the outbreaks were definitively brought under control.⁴

That 54 percent control rate is sobering. It suggests that once Citrobacter establishes itself in a hospital environment, particularly in water systems, standard infection-control protocols may not be enough to eradicate it. Some facilities have had to redesign plumbing fixtures, replace sinks, or install point-of-use water filters to break the chain of transmission. For individual patients, the practical takeaway is that hand hygiene by healthcare workers remains the single most important barrier, and patients or their advocates should feel empowered to remind staff to wash or sanitize their hands before any bedside contact.

Why It Often Gets Overlooked

C. amalonaticus occupies a blind spot in clinical microbiology. It is rare enough that many clinicians go years without encountering a named case, yet common enough in hospital environments that it seeds infections regularly and quietly. Part of the problem is historical: older identification systems sometimes lumped it together with C. koseri because the two species look so similar biochemically.² When an organism is misidentified, its infection rates appear lower than they really are, and its resistance patterns get folded into another species’ data. The wider adoption of MALDI-TOF in clinical labs is gradually correcting this, and the apparent rise in cases documented in the Marseille study may partly reflect better identification rather than a true surge in infections.

The Citrobacter genus in general also suffers from an awareness deficit compared to headline pathogens like MRSA or carbapenem-resistant Klebsiella. Public health surveillance systems and antimicrobial stewardship programs tend to focus on organisms classified as urgent threats, and Citrobacter species have only recently started to appear on some watch lists. As resistance genes continue to accumulate in these organisms, that may change.

Beyond Infections: Industrial Uses of C. Amalonaticus

In an unexpected twist, the same metabolic versatility that makes C. amalonaticus a nuisance in hospitals makes it useful in biotechnology. One strain, designated Y19, has been studied for its ability to produce hydrogen gas from glucose under oxygen-free conditions. Metabolic modeling predicted a theoretical maximum yield of nearly 9 moles of hydrogen per mole of glucose, an impressively efficient conversion rate that has attracted interest from researchers working on biohydrogen as a renewable energy source.¹³

Separately, another C. amalonaticus isolate has been studied for its ability to produce succinic acid, a chemical building block used in biodegradable plastics, food additives, and pharmaceutical intermediates. The bacterium showed the ability to use diverse carbon sources and even fix carbon dioxide during the fermentation process, making it a potential platform for green chemistry applications.¹⁴ A strain isolated from the human gut was found to degrade choline, a nutrient linked to cardiovascular risk when gut bacteria convert it to a compound called trimethylamine. Understanding which gut bacteria process choline and how they do it has implications for cardiovascular disease research.³ The organism’s dual identity, as both an opportunistic pathogen and a metabolic workhorse, is a useful reminder that “harmful” and “useful” are not fixed categories in microbiology but depend entirely on context.